🔗 Share this article

Given that America proceeds with sweeping adjustments to its immunization schedules, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by questioning Covid vaccines during the pandemic and has concentrated on potential fatalities following Covid vaccination in her recent position at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Health officials planned to announce sweeping changes to the pediatric immunization program recently, aligning the US with the Danish immunization schedule, according to reports – a major change that would place the US out of alignment with much of the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s CDER, the fifth appointee to run the center this calendar year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for ending certain pediatric immunization guidelines in the US to become more in line with Denmark's approach, a nation with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Høeg has no obvious background in medication creation, regulation or management, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a major agency. She lacks background in pharmaceutical oversight.”

Past directors of the center would “understand legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who led CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the novel medication approvals, but the generic program approves numerous generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and all of those have to be supervised,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major administrative aspect to the job, which supervises more than 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Controversial Initiatives

When asked about questions about Høeg’s credentials and whether this appointment represents greater collaboration among agency officials on vaccines, a press secretary said that the “inquiries stem from inaccurate assumptions”.

“Her experience is consistent with the duties of her position,” the spokesperson explained, pointing to the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s new priority voucher program, a controversial one-day therapy clearance system that allegedly concerned her former heads. “By what process are these drugs being chosen for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he stated, “the agency appears to be shifting towards laxer oversight of pharmaceuticals, except for immunizations.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if problematic, track record, critics have noted. She published a study using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation after Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the current federal leadership included revising rules for recently developed shots and halting “non-essential” immunizations, she said after the election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an all-around dogmatist who begins with her beliefs and reverse-engineers to fit the evidence in a extremely misleading, untruthful manner,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|